Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD
Merck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung disease, while also succeeding in a separate mid-stage study for ...
August 4, 2026 06:30 AM EDT R&D Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in a rare lung disease Nicole DeFeudis Senior Reporter Merck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that